IL296579A - Antibody against ccl24 for use in a treatment method - Google Patents

Antibody against ccl24 for use in a treatment method

Info

Publication number
IL296579A
IL296579A IL296579A IL29657922A IL296579A IL 296579 A IL296579 A IL 296579A IL 296579 A IL296579 A IL 296579A IL 29657922 A IL29657922 A IL 29657922A IL 296579 A IL296579 A IL 296579A
Authority
IL
Israel
Prior art keywords
ccl24
monoclonal antibody
pharmaceutical composition
administration
antibody
Prior art date
Application number
IL296579A
Other languages
English (en)
Hebrew (he)
Original Assignee
Chemomab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemomab Ltd filed Critical Chemomab Ltd
Publication of IL296579A publication Critical patent/IL296579A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL296579A 2020-04-22 2021-04-20 Antibody against ccl24 for use in a treatment method IL296579A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063013793P 2020-04-22 2020-04-22
PCT/IL2021/050447 WO2021214759A1 (en) 2020-04-22 2021-04-20 Method of treatment using anti-ccl24 antibody

Publications (1)

Publication Number Publication Date
IL296579A true IL296579A (en) 2022-11-01

Family

ID=75787181

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296579A IL296579A (en) 2020-04-22 2021-04-20 Antibody against ccl24 for use in a treatment method

Country Status (9)

Country Link
US (1) US20230235037A1 (cg-RX-API-DMAC7.html)
EP (1) EP4139352A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023522907A (cg-RX-API-DMAC7.html)
KR (1) KR20230013037A (cg-RX-API-DMAC7.html)
CN (1) CN115427445A (cg-RX-API-DMAC7.html)
AU (1) AU2021259682A1 (cg-RX-API-DMAC7.html)
CA (1) CA3172627A1 (cg-RX-API-DMAC7.html)
IL (1) IL296579A (cg-RX-API-DMAC7.html)
WO (1) WO2021214759A1 (cg-RX-API-DMAC7.html)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP4762156B2 (ja) * 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション，インコーポレイテッド Ｆｃ領域変異体
AU2010209273A1 (en) 2009-01-28 2011-09-01 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
CA2777013A1 (en) * 2009-10-16 2011-04-21 Mochida Pharmaceutical Co., Ltd. Marker associated with non-alcoholic steatohepatitis
SG184355A1 (en) * 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
US10246508B2 (en) 2014-03-04 2019-04-02 Chemomab Ltd. Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines
CA2957722C (en) * 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
EP3191126B1 (en) * 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
US20180008707A1 (en) * 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
EP3433274A1 (en) * 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
IL326479A (en) * 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
IL251024A0 (en) * 2017-03-08 2017-06-29 Chemomab Ltd Antibodies against eutaxin 2 for use in the treatment of liver diseases
CN107198773A (zh) * 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂
CA3071234A1 (en) * 2017-07-27 2019-01-31 Daiichi Sankyo Company, Limited Anti-cd147 antibody
CN109745559A (zh) * 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 抗人il-17a的单克隆抗体的液体制剂
CN110354073B (zh) * 2018-04-09 2021-10-01 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂

Also Published As

Publication number Publication date
KR20230013037A (ko) 2023-01-26
CN115427445A (zh) 2022-12-02
WO2021214759A1 (en) 2021-10-28
JP2023522907A (ja) 2023-06-01
US20230235037A1 (en) 2023-07-27
EP4139352A1 (en) 2023-03-01
AU2021259682A1 (en) 2022-10-20
CA3172627A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CN109789194B (zh) 用angptl8抑制剂和angptl3抑制剂治疗高脂血症的方法
IL296519A (en) Anti-igf-1 receptor humanized antibody
IL272321B2 (en) Methods and compositions for treatment of amyloid deposition diseases
IL260931B1 (en) Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
NZ581834A (en) Humanized antibodies to amyloid beta
IL261006A (en) Method and preparation for the treatment of cancer, killing of metastatic cancer cells and prevention of cancer metastases using an antibody to advanced glycation end products
IL263630B2 (en) Stable liquid pharmaceutical preparation
IL270894B (en) Human antibodies to bet v 1 and methods of use thereof
IL272361B1 (en) Antibodies that bind active alpha-synuclein
IL264636B (en) High concentration antibody formulations
CN106103479B (zh) 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体
IL296214A (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
IL298370A (en) Methods of treating iga nephropathy with an april binding antibody
JP7375252B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
IL278978B1 (en) Preparations and methods for treating psoriasis
IL295122A (en) Long-term gm-csf and methods of use
IL300059A (en) Anti-Abata antibodies
IL292029A (en) Humanized antibodies against chemokin like receptor 1 and their therapeutic uses
IL323031A (en) Use of anti-CEACAM5 immunoconjugates for the treatment of neuroendocrine tumors expressing CEACAM5
IL302383A (en) A method for the safe administration of anti-tau antibodies
IL323157A (en) Antitumor combinations containing conjugates of anti-ceacam5 antibodies, anti-vegfr-2 antibodies, and anti-pd1/pd-l1 antibodies
IL297640A (en) Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies
IL298155A (en) Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
IL302386A (en) Methods for reducing tau in humans
JP7798763B2 (ja) Ｃ５関連疾患の治療または予防のための投与レジメン